Triple threat: immunotherapy, chemo, and radiation take on rectal cancer
NCT ID NCT07622771
First seen Jun 06, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This phase 2 trial is testing whether adding an immunotherapy drug (adebrelimab) to a chemotherapy combo (NALIRIFOX) and radiation can improve outcomes for people with a certain type of locally advanced rectal cancer (pMMR/MSS). About 84 participants will be randomly assigned to receive either short-course or long-course radiation along with the drugs. The main goal is to see how many patients have no cancer left after treatment, either from surgery or from a watch-and-wait approach.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, P. R. China
Guangzhou, Guangdong, 510000, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adebrelimab (an immunotherapy drug) plus NALIRIFOX (a combination of chemotherapy drugs: oxaliplatin, liposomal irinotecan, leucovorin, and fluorouracil) plus radiotherapy
What this could lead to
If this works, it could offer a more effective way to shrink rectal tumors before surgery, potentially allowing some patients to avoid surgery altogether.
What could go wrong
This is an early phase 2 trial with only 84 people, so results are not definitive. The combination of drugs and radiation may cause significant side effects, and it may not work better than standard treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.